Madrigal Pharmaceuticals (MDGL) risk factors, FY2024 10-K

Risks Related to the Commercialization and Continued Approval of Rezdiffra

1. 01The commercial success of Rezdiffra will depend on the degree of market acceptance by physicians, patients, third-party payors and others in the health care community
2. 02If the sales and marketing capabilities we have established for the commercialization of Rezdiffra are not effective, Rezdiffra may not be successfully commercialized
3. 03We may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business
4. 04in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs
5. 05the prices of prescription drugs in the government health benefit programs. The IRA or other legislative changes could impact the market conditions for our product candidate
6. 06Rezdiffra remains subject to ongoing regulatory review, and if we fail to comply with continuing regulations, we could lose our approval and the sale of Rezdiffra could be suspended
7. 07Rezdiffra could develop unexpected safety or efficacy concerns, which would likely have a material adverse effect on us
8. 08We operate in a highly competitive and changing environment, and if we are unable to adapt to our environment, we may be unable to compete successfully
9. 09If we are unable to compete successfully, it will materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock
10. 10be successful in these trials or in obtaining such regulatory approval, which may materially adversely affect our prospects and the value of our common stock
11. 11If we do not obtain regulatory approval of Rezdiffra in foreign jurisdictions, we will not be able to market Rezdiffra in other jurisdictions, which will limit our commercial revenues
12. 12Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any
13. 13If the FDA or other applicable regulatory authorities approve generic products that compete with Rezdiffra, the sales of Rezdiffra would be adversely affected
14. 14We currently rely on a limited number of specialty pharmacies for distribution of Rezdiffra in the United States, and the loss of one or more of these specialty pharmacies or their failure to effectively distribute Rezdiffra could materially harm our business
15. 15If estimates of the size of the potential market for Rezdiffra is overstated or data we have used to identify physicians is inaccurate, our ability to earn revenue to support our business could be materially adversely affected
16. 16Product liability lawsuits brought against us could cause us to incur substantial liabilities and could limit commercialization of Rezdiffra or any future product candidates that we may develop

Risks Related to Product Development and Regulatory Approval

1. 17We cannot be certain that any of our ongoing or future clinical trials will be successful, and any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications
2. 18If we fail to develop and commercialize other product candidates, we may be unable to grow our business
3. 19data become available. Differences between preliminary or interim data and final data could significantly harm our business prospects
4. 20If clinical trials or regulatory approval processes are prolonged, delayed or suspended, we may be unable to advance the development of or commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any revenue from potential product sales
5. 21Commercialization of any future product candidates may be delayed by the imposition of additional conditions on our clinical trials by the FDA or any other applicable foreign regulatory authority or the requirement of additional supportive trials by the FDA or such foreign regulatory authority
6. 22If we inadvertently fail to comply with foreign regulatory requirements governing human clinical trials and marketing approval for drugs, we could be prevented from selling our drug candidates in foreign markets, which may adversely affect our operating results and financial condition
7. 23We depend on enrollment of patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
8. 24Breakthrough therapy or priority review by the FDA for any product candidate may not lead to faster development, regulatory review or approval processes, and it does not increase the likelihood that our product candidates will receive marketing approval

Risks Related to our Business Operations, Employee Matters and Managing Growth

1. 25We are dependent upon retaining and attracting key personnel, the loss of whose services could materially adversely affect our business, financial condition, results of operations, prospects and the value of our common stock
2. 26Our employees, contractors, vendors and partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading laws, which could cause significant liability for us and harm our reputation
3. 27We expect to continue to expand our development and commercialization capabilities, and as a result, we may encounter challenges in managing our growth, which could disrupt our operations
4. 28Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products could impair our ability to grow our business
5. 29Any strategic transactions we enter into may not be clinically or commercially successful, and may require financing or a significant amount of cash, which could adversely affect our business
6. 30We may enter into out-licenses or pursue collaborative relationships with entities in foreign jurisdictions outside of the United States and Europe
7. 31We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, such performance could have a material adverse effect on our business, financial condition and results of operations

Risks Related to Our Dependence on Third Parties

1. 32If the third parties on which we rely for the conduct of our clinical trials and results do not perform our clinical trial activities in accordance with GCP and related regulatory requirements, we may be unable to obtain regulatory approval for our product candidates or commercialize our products
2. 33We have relied on, and expect to continue to rely on, third-party manufacturers to produce Rezdiffra and any future product candidates
3. 34Our current and anticipated future dependence upon others for the manufacture of Rezdiffra and any future product candidate may adversely affect our future profit margins, if any, and our ability to develop our product candidates and commercialize any products that receive regulatory approval on a timely basis

Risks Related to Our Financial Position and Need for Capital

1. 35We have a limited operating history and currently only have one commercial product, Rezdiffra in the United States, which may make it difficult to evaluate the prospects for our future viability
2. 36We have a history of operating losses, expect to incur operating losses in the future and may never achieve or maintain profitability
3. 37We have a limited history of recognizing revenue from product sales and may not be able to achieve or maintain long-term sustainable profitability
4. 38We may need to raise additional capital to fund our operations, but we face uncertainties with respect to our ability to access capital. If we are unable to raise capital if and when needed, we could be forced to delay, reduce or eliminate our drug development activities or commercialization efforts
5. 39Our Loan and Security Agreement contains restrictive and financial covenants that may limit our operating flexibility
6. 40Our failure to comply with the covenants or other terms of the Loan Agreement, including as a result of events beyond our control, could result in a default under the Loan Agreement that could materially and adversely affect our business

Risks Related to Government Regulation

1. 41Government healthcare reform could materially increase our costs, which could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock
2. 42The pharmaceutical industry is highly regulated and changes in or revisions to laws and regulations that make gaining regulatory approval, reimbursement and pricing more difficult or subject to different criteria and standards may adversely impact our business, operations or financial results
3. 43Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity, and could negatively affect our operating results and business
4. 44European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information
5. 45Risks associated with operations outside of the United States could adversely affect our business

Risks Related to Our Intellectual Property

1. 46Our success depends on our ability to protect our intellectual property and our proprietary technologies
2. 47Our rights to develop and commercialize our product are subject in part to the terms and conditions of a license to resmetirom granted to us by Roche
3. 48We may fail to comply with any of our obligations under agreements pursuant to which we license rights or technology, which could result in the loss of rights or technology that are material to our business
4. 49If we do not obtain protection under the Hatch-Waxman Act and similar foreign legislation by extending the term of patents covering our product or product candidates, our business may be materially harmed
5. 50Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents
6. 51Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts
7. 52We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court
8. 53We may not be successful in obtaining or maintaining necessary rights to our product and product candidates through acquisitions and in-licenses
9. 54Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
10. 55If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
11. 56We may not be able to protect our intellectual property rights throughout the world

Risks Related to Ownership of Our Common Stock

1. 57The price of our common stock has been, and may continue to be, volatile
2. 58A small number of our stockholders beneficially own a substantial amount of our outstanding common stock and may be deemed to have substantial control over us; therefore, your ability to influence corporate matters may be limited
3. 59stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management, which may depress the trading price of our common stock
4. 60The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 80% of our then-outstanding common stock
5. 61contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction
6. 62Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall
7. 63Sales of a significant number of shares of our common stock in the public markets or significant short sales of our common stock, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital
8. 64We do not anticipate paying cash dividends on our common stock, and accordingly, stockholders must rely on stock appreciation, if any, for any return on their investment
9. 65If securities analysts publish negative evaluations of our stock, the price of our stock could decline
10. 66We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives
11. 67A failure of our information technology infrastructure and cybersecurity threats may adversely affect our business and operations
12. 68We may use and integrate artificial intelligence into our business processes both in our own development and implementation of models and through the adoption of commercially available tools. Use of this technology presents risks and challenges that could affect our business
13. 69If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors' views of us and, as a result, the value of our common stock
14. 70Our NOLs have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits
15. 71Changes in tax law could adversely affect our business and financial condition
16. 72Business disruptions could seriously harm our operations, future revenues and financial condition and increase our costs and expenses
17. 73We may be subject to securities litigation, which is expensive and could divert management attention